A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Clinical trial NCT06417814 · RECRUITING
Trial details
- NCT number
- NCT06417814
- Sponsor
- AstraZeneca
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-10-04
- Primary completion
- 2026-09-30
- Enrollment
- 744
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.